Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SANOFI.NS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
-20%
82.67
vs 103.51
Q2.23
+2%
53.36
vs 52.28
Q3.23
+16%
65.95
vs 56.84
Q4.23
+5%
59.79
vs 56.84
Q1.24
-28%
59.31
vs 82.67
Q2.24
-16%
44.81
vs 53.36
Q3.24
-46%
35.69
vs 65.95
Q4.24
-34%
39.64
vs 59.79
Q1.25
-25%
44.4
vs 59.31
Q2.25
-22%
34.8
vs 44.81
Sales Growth
YoY
Current
Estimates
Q1.23
+4%
7.4B vs 7.1B
Q2.23
+1%
7.1B vs 7B
Q3.23
+3%
7.1B vs 6.9B
Q4.23
+3%
6.9B vs 6.7B
Q1.24
-1%
7.3B vs 7.4B
Q2.24
-34%
4.6B vs 7.1B
Q3.24
-27%
5.2B vs 7.1B
Q4.24
-26%
5.1B vs 6.9B
Q1.25
-25%
5.5B vs 7.3B
Q2.25
+4%
4.8B vs 4.6B
Return on Equity
QoQ
Q1.23
+15%
0.15
vs 0.1
Q2.23
+17%
0.17
vs 0.15
Q3.23
+21%
0.21
vs 0.17
Q4.23
+14%
0.14
vs 0.21
Q1.24
+13%
0.13
vs 0.14
Q2.24
+15%
0.15
vs 0.13
Q3.24
NA
NA
vs 0.15
Q4.24
+11%
0.11
vs NA
Institutionnal Ownership
Relative Strength
SANOFI.NS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
NSE
19.00Â ( 0.31%)
Relative Strenght
Volume Buzz
-71%
Earning Acce
No
Dist 52w H.
41%Forecast
310%2025-Revenue
330%2025-EPS
408%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SANOFI.NS compares to sector?